GENE202 is a single dose gene therapy for patients with rare metabolic disease, methylmalonic acidaemia.

The global cell and gene therapy market is experiencing explosive growth. Key growth factors include rising chronic/genetic disease prevalence, advancements in gene editing (CRISPR) and viral vectors, ...

To discover more about Nature’s Fynd, visit. To learn about their remarkable nutritional fungi protein and fermentation ...

The market size of CGT products is expected to continue to rise by 2031 and reach $63 billion. CGTs have yielded commercial gains for several pharma companies. For example, some of the top-selling CGT ...

Experimental gene therapies like AMT‑130 lower toxic huntingtin protein and significantly slow Huntington’s disease, offering ...

ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, today announced the ...

Is Obesity Genetic or Environmental? Get All the Details This article was reviewed by Lynn Marie Morski, MD, JD. Key ...

OCU410 controlled lesion growth 46% better than placebo in dAMD-related GA.

"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are common-sense reforms that will address the unique characteristics of cell and ...

Join the ELRIG conference to hear from experts on cell and gene therapy. Discover advancements shaping the future of medicine.

Cell and gene therapies present promising opportunities, especially in oncology, blood disorders, and neurology. Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...